Are semaglutide tablets the same as Ozempic?

You've searched 'semaglutide tablets' and ended up more confused than when you started

That's a reasonable place to be. The name semaglutide appears across several products, several conditions and a good deal of online noise, so it's genuinely hard to work out which one relates to weight loss and which doesn't. The short version: semaglutide is a GLP-1 receptor agonist, it works by mimicking a gut hormone that tells the brain you're full and slows the rate at which your stomach empties. Eli Lilly didn't develop it; Novo Nordisk did, and they hold all three UK-licensed semaglutide products. What differs between them is the dose, the delivery method, the indication, and critically, the licence the MHRA has granted. Ozempic contains 0.5 mg, 1 mg or 2 mg semaglutide per weekly injection, and those are doses calibrated for blood-sugar control in type 2 diabetes. The Wegovy tablet, approved in June 2026, titrates from 1.5 mg up to a 25 mg daily maintenance dose, far higher figures, because oral absorption of semaglutide is substantially lower than subcutaneous injection, so the dose must be much larger to get the same effect. Rybelsus sits in the middle (3 mg, 7 mg, 14 mg tablets), but it's also a diabetes product. The names behind semaglutide tablets can help you keep track of which is which.

Why Ozempic isn't (and can't be) a substitute for a weight-loss tablet

The MHRA licenses a medicine for a specific indication based on the clinical trial data submitted for that indication. Ozempic's trial programme was built around glycaemic control in adults with type 2 diabetes. The dose range studied, the endpoints measured, the safety monitoring put in place, all of it was designed for that population. When people take Ozempic for weight loss, they are using an off-label dose of a diabetes medicine, outside a formal clinical programme, often without the structured monitoring that the actual weight-loss products carry. The NHS semaglutide medicines page is unambiguous: Ozempic is for type 2 diabetes. The fact that semaglutide suppresses appetite at any dose does not mean every semaglutide product is equivalent to Wegovy for weight management purposes. Wegovy (both the injection and the newer tablet) was studied in large dedicated weight-management trials. The OASIS 4 trial, the phase 3 study behind the Wegovy tablet's approval, enrolled adults specifically with obesity or overweight plus a weight-related condition, running for 64 weeks, that's the evidence base the MHRA evaluated. Everything the Wegovy tablet licence covers is set out in detail if you want the full clinical picture. The distinction between a medicine that happens to cause weight loss and one licensed to treat obesity is not a technicality, it shapes the clinical support, the monitoring and the prescribing framework you receive.

What is actually licensed for weight loss in the UK, and what that means practically

Two medicines are licensed in the UK for weight management: semaglutide (as Wegovy, injection or tablet) and tirzepatide (as Mounjaro, a once-weekly injection). Both require a prescription following a clinical assessment, that's not a formality, it's how the licensing works. The semaglutide tablets page covers the Wegovy tablet's dosing schedule and what to expect from the titration. The Wegovy tablet is taken first thing in the morning on an empty stomach with a small amount of plain water, then you wait at least 30 minutes before eating, drinking coffee or taking any other oral medicines, so practically, it's a case of taking it before the kettle finishes boiling and building that gap into your morning. No refrigeration needed, which makes it genuinely easier to fit into daily life than an injection kept in the fridge. Rybelsus versus semaglutide for weight loss is another question worth reading through if you've seen Rybelsus mentioned and wondered whether it applies to you. It doesn't, for weight loss, but the article explains the distinction clearly. If you're considering Mounjaro instead, the weight-loss treatment overview sets out both licensed options side by side. For a route into clinical assessment, our prescribers are available for a free consultation, they can help you work out which licensed treatment, if any, is the right fit.